Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the Intestine Cancer Therapeutics market right now?
The market size of therapeutics for intestine cancer has witnessed robust growth in the recent past. This market is projected to expand from $14 billion in 2024 to $15.26 billion in 2025, manifesting a compound annual growth rate (CAGR) of 9.0%. The growth during the historical period is a result of progression in medical research, a surge in cancer cases, improved chemotherapy and radiology treatments, initiatives towards early detection and screening, along with discoveries of genetics and biomarkers.
How fast Is the intestine cancer therapeutics market expected to grow, and what’s its future value?
The market for therapeutics related to intestine cancer is projected to experience substantial growth in the upcoming years. The market is predicted to reach a value of $21.15 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.5%. This growth in the forecast period is credited to developments in immunotherapy, precision medicine and personalized treatments, the emergence of targeted therapies, and the incorporation of artificial intelligence (AI), and patient-focused methodologies. The main trends to watch in this forecast period include technologies for liquid biopsies, research in precision medicine and biomarkers, combination treatments, patient-centered care along with supportive therapies, and the use of minimally invasive surgical methods.
Get your intestine cancer therapeutics market report here!
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
What are the leading drivers of growth in the intestine cancer therapeutics market?
The rising incidence of hereditary colorectal cancer syndromes is predicted to fuel the expansion of the intestine cancer therapeutics market. These syndromes consist of hereditary genetic variants that enhance a person’s susceptibility to developing colorectal cancer. Their significant contribution to intestinal cancer therapeutics lies in providing insights related to specific genetic mutations that greatly amplify colorectal cancer risk. For instance, the World Health Organization declared in July 2023 that the number of hereditary colorectal cancer cases is anticipated to significantly rise by 2040, with an estimated 3.2 million new instances and 1.6 million deaths each year. This denotes a 63% and 73% surge in new cases and fatalities respectively as compared to the present figures. Hence, the escalating incidence of hereditary colorectal cancer syndromes is a key driver of the intestine cancer therapeutics market’s growth.
Intestine Cancer Therapeutics Market Driver: Personalized Medicine Catalyzing The Growth Of The Intestine Cancer Therapeutics Market
What are the key segments defining the intestine cancer therapeutics market?
The intestine cancer therapeutics market covered in this report is segmented –
1) By Treatment Type: Immunotherapy, Chemotherapy, Other Treatments
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Hospitals, Homecare, Specialty Centers, Other Applications
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines
2) By Chemotherapy: Adjuvant Chemotherapy, Neoadjuvant Chemotherapy, Palliative Chemotherapy
3) By Other Treatments: Targeted Therapy, Radiation Therapy, Surgery, Hormone Therapy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp
Who are the key players steering the development of the intestine cancer therapeutics market?
Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited
What emerging trends are influencing the growth of the intestine cancer therapeutics market?
Leading enterprises in the intestinal cancer therapeutics market are focusing on the creation of unique products such as Lonsurf to cater to a wider customer base and enhance their sales and revenue. LONSURF, which is a fusion of two drugs – trifluridine and tipiracil, is designed for the treatment of metastatic colorectal cancer in adults. Taiho Oncology Inc., a pharmaceutical company based in the US, was granted approval for Lonsurf by the US Food and Drug Administration in August 2023. Lonsurf is offered as a single tablet meant for oral consumption. Trifluridine serves to halt the growth of cancer cells and tipiracil enhances the effectiveness of trifluridine by preventing its breakdown inside the body. This approval makes Lonsurf a new treatment choice which potentially benefits patients with metastatic colorectal cancer and others eligible, by potentially improving their outcomes and enriching their quality of life.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13231
Which regions are most influential in expanding the intestine cancer therapeutics market?
Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Anti-Inflammatory Therapeutics Global Market Report 2024
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2024
Digital Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
